Cutting Edge: Mast Cells Regulate Disease Severity in a Relapsing-Remitting Model of Multiple Sclerosis

被引:66
作者
Sayed, Blayne A. [1 ]
Walker, Margaret E. [1 ]
Brown, Melissa A. [1 ]
机构
[1] Northwestern Univ, Dept Microbiol & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; BALB/C INBRED STRAINS; MICE; INFLAMMATION; ACTIVATION; INFECTION; HISTAMINE; VIRUS;
D O I
10.4049/jimmunol.1003574
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mast cells (MCs) exert a significant pathologic influence on disease severity in C57BL/6 (B6) strain-dependent experimental allergic encephalomyelitis (EAE), a model of primary progressive multiple sclerosis (MS). However, relapsing-remitting MS, which is modeled in SJL mice, is the more prevalent form. Given genetically determined heterogeneity in numbers and responsiveness of MCs from various strains of mice, we asked whether these cells also influence this more clinically relevant MS model using SJL-Kit(W/W-v) mice. Similar to the commercially available WBB6F(1)-Kit(W/W-v) mice, SJL-Kit(W/W-v) mice are MC-deficient, anemic, and neutropenic and have normal T cell compartments. They exhibit significantly reduced disease severity, but retain the relapsing-remitting course, a phenotype reversed by selective MC reconstitution. These data confirm that MC influence is not confined to an isolated model of EAE and reveal a new system to study the effects of MC heterogeneity on relapsing-remitting EAE and other SJL strain-specific diseases. The Journal of Immunology, 2011, 186: 3294-3298.
引用
收藏
页码:3294 / 3298
页数:5
相关论文
共 50 条
  • [1] Cytoprotective E-WE thrombin reduces disease severity in a murine model of relapsing-remitting multiple sclerosis
    Verbout, Norah G.
    Su, Weiping
    Pham, Peter
    Jordan, Kelley R.
    Kohs, Tia C. L.
    Tucker, Erik I.
    McCarty, Owen J. T.
    Sherman, Larry S.
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2024, 326 (01): : C40 - C49
  • [2] IL-15 Is Overexpressed in γδ T Cells and Correlates with Disease Severity in Relapsing-Remitting Multiple Sclerosis
    Zarobkiewicz, Michal K.
    Kowalska, Wioleta
    Morawska, Izabela
    Halczuk, Pawel
    Rejdak, Konrad
    Bojarska-Junak, Agnieszka
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (18)
  • [3] Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
    Johnson, Kenneth P.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (04) : 371 - 384
  • [4] B Cells as a Therapeutic Target for IFN-β in Relapsing-Remitting Multiple Sclerosis
    Ramgolam, Vinod S.
    Sha, Yonggang
    Marcus, Karen L.
    Choudhary, Neelima
    Troiani, Luigi
    Chopra, Manisha
    Markovic-Plese, Silva
    JOURNAL OF IMMUNOLOGY, 2011, 186 (07) : 4518 - 4526
  • [5] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [6] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [7] Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis
    Buscarinu, M. C.
    Romano, S.
    Mechelli, R.
    Umeton, R. Pizzolato
    Ferraldeschi, M.
    Fornasiero, A.
    Renie, R.
    Cerasoli, B.
    Morena, E.
    Romano, C.
    Loizzo, N. D.
    Umeton, R.
    Salvetti, M.
    Ristori, G.
    NEUROTHERAPEUTICS, 2018, 15 (01) : 68 - 74
  • [8] An update on cladribine for relapsing-remitting multiple sclerosis
    Holmoy, Trygve
    Torkildsen, Oivind
    Myhr, Kjell-Morten
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1627 - 1635
  • [9] Acthar gel treatment suppresses acute exacerbations in a murine model of relapsing-remitting multiple sclerosis
    Cusick, Matthew F.
    Libbey, Jane E.
    Oh, Luke
    Jordan, Shaun
    Fujinami, Robert S.
    AUTOIMMUNITY, 2015, 48 (04) : 222 - 230
  • [10] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis
    Miller, Aaron E.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 181 - 194